GSK executive acquires ADS in savings plan

GSK plc reported that senior executive Maya Martinez-Davis, President, acquired notional American Depositary Shares through the GSK Executive Supplemental Savings Plan.

Rhea-AI Filing Summary

GSK plc reported that senior executive Maya Martinez-Davis, President, acquired notional American Depositary Shares through the GSK Executive Supplemental Savings Plan. The transaction involved 129.152 ADS at a price of $53.3900 per ADS on 2026-03-13 on the New York Stock Exchange.

These are plan-related notional ADS rather than a standard open-market purchase, reflecting additional equity-linked compensation within her executive savings account.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GSK (GSK) disclose in this Form 6-K?

GSK disclosed that executive Maya Martinez-Davis acquired notional American Depositary Shares through the GSK Executive Supplemental Savings Plan. She obtained 129.152 ADS at $53.3900 each on March 13, 2026, via a transaction conducted on the New York Stock Exchange.

Who is the GSK (GSK) executive involved in the March 2026 ADS transaction?

The transaction involves Maya Martinez-Davis, who serves as President at GSK. She acquired notional ADS units within her GSK Executive Supplemental Savings Plan account, reflecting equity-linked compensation rather than a standard open-market purchase of American Depositary Shares.

How many GSK (GSK) ADS did the executive acquire and at what price?

Maya Martinez-Davis acquired 129.152 notional American Depositary Shares of GSK at a price of $53.3900 per ADS. The acquisition occurred within her GSK Executive Supplemental Savings Plan account as a single transaction reported in this Form 6-K filing.

When and where was the GSK (GSK) ADS transaction carried out?

The transaction was carried out on March 13, 2026, on the New York Stock Exchange, identified as XNYS. It involved acquisition of notional American Depositary Shares for Maya Martinez-Davis’s GSK Executive Supplemental Savings Plan account, as disclosed in the Form 6-K report.

What type of instrument was involved in the GSK (GSK) executive transaction?

The instrument was GSK American Depositary Shares, identified by ISIN US37733W2044. These ADS represent equity in GSK and were acquired on a notional basis within the company’s Executive Supplemental Savings Plan for President Maya Martinez-Davis, rather than as a straightforward cash stock purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 02:36 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

​

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$53.3900	129.152
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-03-13
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: March 17, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc